Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases

Current Pharmaceutical Design

Volumn 18, Issue 7, 2012, Pages 875-883

  Niitsu, Tomihisa ^a   Iyo, Masaomi ^a,b   Hashimoto, Kenji ^b  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Cognition; Delirium; Psychotic depression; Schizophrenia; Sigma 1 receptor

Indexed keywords

CUTAMESINE; DONEPEZIL; FLUVOXAMINE; NEUROSTEROID; OPIATE AGONIST; PRASTERONE; PRASTERONE SULFATE; PREGNENOLONE; SERTRALINE; SIGMA 1 RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANTIDEPRESSANT ACTIVITY; ARTICLE; BINDING AFFINITY; COGNITION; COGNITIVE DEFECT; DELIRIUM; DEPRESSIVE PSYCHOSIS; DRUG BINDING SITE; DRUG EFFECT; ELECTROCONVULSIVE THERAPY; HUMAN; IN VITRO STUDY; MAJOR DEPRESSION; MENTAL DISEASE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE DRUG DOSE;

ANIMALS; COGNITION DISORDERS; HUMANS; MENTAL DISORDERS; NOOTROPIC AGENTS; RECEPTORS, SIGMA;

EID: 84857134134     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799436476     Document Type: Article

References (144)

1. Freedman R. Schizophrenia. N Engl J Med 2003; 349: 1738-49.
2. Coyle JT, Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) 2004; 174: 32-38.
3. Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 2004; 56: 301-7.
4. Kurtz MM. Neurocognitive impairment across the lifespan in schizophrenia: an update. Schizophr Res 2005; 74: 15-26.
5. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007; 64: 633-47.
6. Widlocher DJ. Psychomotor retardation: clinical, theoretical, and psychometric aspects. Psychiatr Clin North Am 1983; 6: 27-40.
7. Fava M. Symptoms of fatigue and cognitive/executive dysfunction in major depressive disorder before and after antidepressant treatment. J Clin Psychiatry 2003; 64 (Suppl 14): 30-4.
8. Cohen RM, Weingartner H, Smallberg SA, Pickar D, Murphy DL. Effort and cognition in depression. Arch Gen Psychiatry 1982; 39: 593-7.
9. Porter RJ, Gallagher P, Thompson JM, Young AH. Neurocognitive impairment in drug-free patients with major depressive disorder. Br J Psychiatry 2003; 182: 214-20.
10. Hashimoto K, Koike K, Shimizu E, Iyo M. α7 Nicotinic receptor agonists as potential therapeutic drugs for schizophrenia. Curr Med Chem CNS Agents 2005; 5: 171-84.
11. Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull 2007; 33: 1120-30.
12. Hashimoto K. Glycine transport inhibitors for the treatment of schizophrenia. Open Med Chem J 2010; 4: 10-9.
13. Toyohara J, Hashimoto K. alpha7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer's Disease. Open Med Chem J 2010; 4: 37-56.
14. Ishikawa M, Hashimoto K. alpha7 nicotinic acetylcholine receptor as a potential therapeutic target for schizophrenia. Curr Pharm Des 2011; 17: 121-9.
15. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine-and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976; 197: 517-32.
16. Hanner M, Moebius FF, Flandorfer A, et al. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci USA 1996; 93: 8072-7.
17. 2+ concentration. J Pharmacol Exp Ther 2000; 293: 788-98.
18. 2+ signaling and cell survival. Cell 2007; 131: 596-610.
19. Hayashi T, Rizzuto R, Hajnoczky G, Su TP. MAM: more than just a housekeeper. Trends Cell Biol 2009; 19: 81-8.
20. Hayashi T, Stahl SM. The sigma-1 receptor and its role in the treatment of mood disorders. Drugs Future 2009; 34: 137-46.
21. Maurice T, Urani A, Phan VL, Romieu P. The interaction between neuroactive steroids and the sigma-1 receptor function: behavioral consequences and therapeutic opportunities. Brain Res Brain Res Rev 2001; 37: 116-32.
22. Maurice T. Improving Alzheimer's Disease-Related Cognitive Deficits with sigma1 Receptor Agonists. Drug News Perspect 2002; 15: 617-25.
23. Su TP, Hayashi T. Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr Med Chem 2003; 10: 2073-80.
24. Hayashi T, Su TP. Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs 2004; 18: 269-84.
25. Hayashi T, Su T. The sigma receptor: evolution of the concept in neuropsychopharmacology. Curr Neuropharmacol 2005; 3: 267-80.
26. 2+: clinical and therapeutic relevance. Biol Cell 2005; 97: 873-83.
27. Hashimoto K, Ishiwata K. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des 2006; 12: 3857-76.
28. Maurice T, Gregoire C, Espallergues J. Neuro(active)steroids actions at the neuromodulatory sigma1 (sigma-1) receptor: biochemical and physiological evidences, consequences in neuroprotection. Pharmacol Biochem Behav 2006; 84: 581-97.
29. Hayashi T, Su TP. An update on the development of drugs for neuropsychiatric disorders: focusing on the sigma-1 receptor ligand. Expert Opin Ther Targets 2008; 12: 45-58.
30. Hashimoto K. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Cent Nerv Syst Agents Med Chem 2009; 9: 197-204.
31. Maurice T, Su TP. The pharmacology of sigma-1 receptors. Pharmacol Ther 2009; 124: 195-206.
32. Ishikawa M, Hashimoto K. The role of sigma-1 receptors in the pathophysiology of neuropsychiatric deseases. J Receptor Ligand Channel Res 2010; 3: 25-36.
33. Su TP, Hayashi T, Maurice T, Buch S, Ruoho AE. The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol Sci 2010; 33: 557-66.
34. Hayashi T, Tsai SY, Mori T, Fujimoto M, Su TP. Targeting ligandoperated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders. Expert Opin Ther Targets 2011; 15: 557-77.
35. Hayashi T, Su TP. Sigma-1 receptors at galactosylceramideenriched lipid microdomains regulate oligodendrocyte differentiation. Proc Natl Acad Sci USA 2004; 101: 14949-54.
36. Tsai SY, Hayashi T, Harvey BK, et al. Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving Rac1xGTP pathway. Proc Natl Acad Sci USA 2009; 106: 22468-73.
37. Harrison PJ, Law AJ. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry 2006; 60: 132-40.
38. Walterfang M, Wood SJ, Velakoulis D, Pantelis C. Neuropathological, neurogenetic and neuroimaging evidence for white matter pathology in schizophrenia. Neurosci Biobehav Rev 2006; 30: 918-48.
39. Fields RD. White matter in learning, cognition and psychiatric disorders. Trends Neurosci 2008; 31: 361-70.
40. van Spronsen M, Hoogenraad CC. Synapse pathology in psychiatric and neurologic disease. Curr Neurol Neurosci Rep 2010; 10: 207-14.
41. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002; 34: 13-25.
42. Stahl SM. Not so selective serotonin reuptake inhibitors. J Clin Psychiatry 1998; 59: 343-4.
43. Stahl SM. Using secondary binding properties to select a not so selective serotonin reuptake inhibitor. J Clin Psychiatry 1998; 59: 642-3.
44. Nemeroff CB, Owens MJ. Pharmacologic differences among the SSRIs: focus on monoamine transporters and the HPA axis. CNS Spectr 2004; 9: 23-31.
45. Narita N, Hashimoto K, Tomitaka S, Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 1996; 307: 117-9.
46. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997; 54: 597-606.
47. Hashimoto K, Shimizu E, Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev 2004; 45: 104-14.
48. Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology 2007; 32: 514-21.
49. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 2010; 64: 341-57.
50. Takebayashi M, Hayashi T, Su TP. Nerve growth factor-induced neurite sprouting in PC12 cells involves sigma-1 receptors: implications for antidepressants. J Pharmacol Exp Ther 2002; 303: 1227-37.
51. Okuyama S, Nakazato A. NE-100: A Novel Sigma Receptor Antagonist. CNS Drug Reviews 1996; 2: 226-37.
52. Nishimura T, Ishima T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS ONE 2008; 3: e2558.
53. Matsuno K, Mita S. SA4503: A Novel Sigma1 Receptor Agonist. CNS Drug Reviews 1998; 4: 1-24.
54. Hashimoto K, Scheffel U, London ED. In vivo labeling of sigma receptors in mouse brain with [3H]4-phenyl-1-(4-phenylbutyl) piperidine. Synapse 1995; 20: 85-90.
55. Takahashi H, Kirsch JR, Hashimoto K, London ED, Koehler RC, Traystman RJ. PPBP [4-phenyl-1-(4-phenylbutyl) piperidine], a potent sigma-receptor ligand, decreases brain injury after transient focal ischemia in cats. Stroke 1995; 26: 1676-82.
56. Takahashi H, Kirsch JR, Hashimoto K, London ED, Koehler RC, Traystman RJ. PPBP [4-phenyl-1-(4-phenylbutyl) piperidine] decreases brain injury after transient focal ischemia in rats. Stroke 1996; 27: 2120-3.
57. Noda Y, Kamei H, Kamei Y, Nagai T, Nishida M, Nabeshima T. Neurosteroids ameliorate conditioned fear stress: an association with sigma receptors. Neuropsychopharmacology 2000; 23: 276-84.
58. Maurice T, Phan VL, Urani A, Guillemain I. Differential involvement of the sigma(1) (sigma-1) receptor in the anti-amnesic effect of neuroactive steroids, as demonstrated using an in vivo antisense strategy in the mouse. Br J Pharmacol 2001; 134: 1731-41.
59. Ishima T, Nishimura T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: role of sigma-1 receptors and IP3 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1656-9.
60. van Waarde A, Ramakrishnan NK, Rybczynska AA, et al. The cholinergic system, sigma-1 receptors and cognition. Behav Brain Res 2011; 221: 543-54.
61. Earley B, Burke M, Leonard BE, Gouret CJ, Junien JL. Evidence for an anti-amnesic effect of JO 1784 in the rat: a potent and selective ligand for the sigma receptor. Brain Res 1991; 546: 282-6.
62. Matsuno K, Senda T, Matsunaga K, Mita S. Ameliorating effects of sigma receptor ligands on the impairment of passive avoidance tasks in mice: involvement in the central acetylcholinergic system. Eur J Pharmacol 1994; 261: 43-51.
63. Kobayashi T, Matsuno K, Mita S. Regional differences of the effect of sigma receptor ligands on the acetylcholine release in the rat brain. J Neural Transm 1996; 103: 661-9.
64. Kobayashi T, Matsuno K, Nakata K, Mita S. Enhancement of acetylcholine release by SA4503, a novel sigma-1 receptor agonist, in the rat brain. J Pharmacol Exp Ther 1996; 279: 106-13.
65. Antonini V, Prezzavento O, Coradazzi M, et al. Anti-amnesic properties of (+/-)-PPCC, a novel sigma receptor ligand, on cognitive dysfunction induced by selective cholinergic lesion in rats. J Neurochem 2009; 109: 744-54.
66. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-8.
67. Hashimoto K, Fukushima T, Shimizu E, et al. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 2003; 60: 572-6.
68. Hashimoto K, Okamura N, Shimizu E, Iyo M. Glutamate Hypothesis of Schizophrenia and Approach for Possible Therapeutic Drugs. Curr Med Chem-Central Nervous System Agents 2004; 4: 147-54.
69. Hashimoto K, Shimizu E, Iyo M. Dysfunction of Glia-Neuron Communication in Pathophysiology of Schizophrenia. Curr Psychiatry Rev 2005; 1: 151-63.
70. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009; 61: 105-23.
71. Hashimoto K. Role of the mTOR signaling pathway in the rapid antidepressant action of ketamine. Expert Rev Neurother 2011; 11: 33-6.
72. Hashimoto K, Fujita Y, Shimizu E, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur J Pharmacol 2005; 519: 114-7.
73. Ishima T, Fujita Y, Kohno M, et al. Improvement of Phencyclidine-Induced Cognitive Deficits in Mice by Subsequent Subchronic Administration of Fluvoxamine, but not Sertraline. Open Clin Chem J 2009; 2: 7-11.
74. Kunitachi S, Fujita Y, Ishima T, et al. Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: role of sigma-1 receptors. Brain Res 2009; 1279: 189-96.
75. Kato K, Hayako H, Ishihara Y, Marui S, Iwane M, Miyamoto M. TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons. Neurosci Lett 1999; 260: 5-8.
76. Maurice T, Meunier J, Feng B, Ieni J, Monaghan DT. Interaction with sigma-1 protein, but not N-methyl-D-aspartate receptor, is involved in the pharmacological activity of donepezil. J Pharmacol Exp Ther 2006; 317: 606-14.
77. Meunier J, Ieni J, Maurice T. Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. J Pharmacol Exp Ther 2006; 317: 1307-19.
78. Meunier J, Ieni J, Maurice T. The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br J Pharmacol 2006; 149: 998-1012.
79. Baulieu EE. Neurosteroids: a novel function of the brain. Psychoneuroendocrinology 1998; 23: 963-87.
80. Charalampopoulos I, Remboutsika E, Margioris AN, Gravanis A. Neurosteroids as modulators of neurogenesis and neuronal survival. Trends Endocrinol Metab 2008; 19: 300-7.
81. Rupprecht R, di Michele F, Hermann B, et al. Neuroactive steroids: molecular mechanisms of action and implications for neuropsychopharmacology. Brain Res Brain Res Rev 2001; 37: 59-67.
82. Monnet FP, Maurice T. The sigma1 protein as a target for the nongenomic effects of neuro(active)steroids: molecular, physiological, and behavioral aspects. J Pharmacol Sci 2006; 100: 93-118.
83. Strous RD, Maayan R, Weizman A. The relevance of neurosteroids to clinical psychiatry: from the laboratory to the bedside. Eur Neuropsychopharmacol 2006; 16: 155-69.
84. 11C]SA4503. Biol Psychiatry 2007; 62: 878-83.
85. 11C]SA4503. Int J Neuropsychopharmacol 2009; 12: 1127-31.
86. Weissman AD, Casanova MF, Kleinman JE, London ED, De Souza EB. Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol Psychiatry 1991; 29: 41-54.
87. Helmeste DM, Tang SW, Bunney WE, Jr., Potkin SG, Jones EG. Decrease in sigma but no increase in striatal dopamine D4 sites in schizophrenic brains. Eur J Pharmacol 1996; 314: R3-5.
88. Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebocontrolled study. Biol Psychiatry 1992; 31: 698-704.
89. Silver H, Shmugliakov N. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. J Clin Psychopharmacol 1998; 18: 208-11.
90. Silver H, Barash I, Aharon N, Kaplan A, Poyurovsky M. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. Int Clin Psychopharmacol 2000; 15: 257-61.
91. Iyo M, Shirayama Y, Watanabe H, et al. Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1072-3.
92. Niitsu T, Shirayama Y, Fujisaki M, Hashimoto K, Iyo M. Fluvoxamine improved cognitive impairments in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1345-6.
93. Goldman S. Possible antipsychotic effect of fluvoxamine. CNS Spectr 2005; 10: 774; author reply 774-5.
94. Niitsu T, Fujisaki M, Shiina A, et al. A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study. submitted (revision).
95. Erickson SK, Schwarzkopf SB, Palumbo D, Badgley-Fleeman J, Smirnow AM, Light GA. Efficacy and tolerability of low-dose donepezil in schizophrenia. Clin Neuropharmacol 2005; 28: 179-84.
96. Risch SC, Horner MD, McGurk SR, et al. Donepezil effects on mood in patients with schizophrenia and schizoaffective disorder. Int J Neuropsychopharmacol 2006; 9: 603-5.
97. Risch SC, Horner MD, McGurk SR, et al. Double-blind donepezilplacebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study. Schizophr Res 2007; 93: 131-5.
98. Marx CE, Keefe RS, Buchanan RW, et al. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology 2009; 34: 1885-903.
99. Hashimoto K. Neurosteroid pregnenolone and sigma-1 receptor function. Clin Psychopharmacol Neurosci 2010; 8: 115.
100. Strous RD, Maayan R, Lapidus R, et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry 2003; 60: 133-41.
101. Nachshoni T, Ebert T, Abramovitch Y, et al. Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Schizophr Res 2005; 79: 251-6.
102. Ritsner MS, Gibel A, Ratner Y, Tsinovoy G, Strous RD. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychopharmacol 2006; 26: 495-9.
103. Strous RD, Stryjer R, Maayan R, et al. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, doubleblind placebo controlled trial. Psychoneuroendocrinology 2007; 32: 96-105.
104. Strous RD, Gibel A, Maayan R, Weizman A, Ritsner MS. Hormonal response to dehydroepiandrosterone administration in schizophrenia: findings from a randomized, double-blind, placebocontrolled, crossover study. J Clin Psychopharmacol 2008; 28: 456-9.
105. Ritsner MS, Gibel A, Shleifer T, et al. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. J Clin Psychiatry 2010; 71: 1351-62.
106. Ribeiz SR, Bassitt DP, Arrais JA, Avila R, Steffens DC, Bottino CM. Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. CNS Drugs 2010; 24: 303-17.
107. Ritsner MS. Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trials. CNS Neurosci Ther 2010; 16: 32-44.
108. Brewer WJ, Francey SM, Wood SJ, et al. Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am J Psychiatry 2005; 162: 71-8.
109. Hashimoto K. Can the sigma-1 receptor agonist fluvoxamine prevent schizophrenia? CNS Neurol Disord Drug Targets 2009; 8: 470-4.
110. Tadokoro S, Kanahara N, Kikuchi S, Hashimoto K, Iyo M. Fluvoxamine prevents onset of psychosis: a case report of a patient at ultra-high risk of psychotic disorder. Ann. Gen. Psychiatry 2011; 10: 26.
111. Matsuno K, Kobayashi T, Tanaka MK, Mita S. Sigma-1 receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test. Eur J Pharmacol 1996; 312: 267-71.
112. Tottori K, Miwa T, Uwahodo Y, et al. Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology 2001; 41: 976-88.
113. Urani A, Roman FJ, Phan VL, Su TP, Maurice T. The antidepressant-like effect induced by sigma-1-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J Pharmacol Exp Ther 2001; 298: 1269-79.
114. Bermack JE, Debonnel G. The role of sigma receptors in depression. J Pharmacol Sci 2005; 97: 317-36.
115. Sabino V, Cottone P, Parylak SL, Steardo L, Zorrilla EP. Sigma-1 receptor knockout mice display a depressive-like phenotype. Behav Brain Res 2009; 198: 472-6.
116. Zarate CA, Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856-64.
117. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized addon trial of an N-methyl-D-aspartate antagonist in treatmentresistant bipolar depression. Arch Gen Psychiatry 2010; 67: 793-802.
118. Hustveit O, Maurset A, Oye I. Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol 1995; 77: 355-9.
119. Stahl SM. The sigma enigma: Can sigma receptors provide a novel target for disorders of mood and cognition? J Clin Psychiatry 2008; 69: 1673-74.
120. Coryell W. The treatment of psychotic depression. J Clin Psychiatry 1998; 59: 22-7; discussion 28-9.
121. Schatzberg AF. New approaches to managing psychotic depression. J Clin Psychiatry 2003; 64: 19-23.
122. Dannon PN, Lowengrub K, Gonopolski Y, Kotler M. Current and emerging somatic treatment strategies in psychotic major depression. Expert Rev Neurother 2006; 6: 73-80.
123. Vythilingam M, Chen J, Bremner JD, Mazure CM, Maciejewski PK, Nelson JC. Psychotic depression and mortality. Am J Psychiatry 2003; 160: 574-6.
124. Hamoda HM, Osser DN. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on psychotic depression. Harv Rev Psychiatry 2008; 16: 235-47.
125. Belanoff JK, Kalehzan M, Sund B, Fleming Ficek SK, Schatzberg AF. Cortisol activity and cognitive changes in psychotic major depression. Am J Psychiatry 2001; 158: 1612-16.
126. Fleming SK, Blasey C, Schatzberg AF. Neuropsychological correlates of psychotic features in major depressive disorders: a review and meta-analysis. J Psychiatr Res 2004; 38: 27-35.
127. Gomez RG, Fleming SH, Keller J, et al. The neuropsychological profile of psychotic major depression and its relation to cortisol. Biol Psychiatry 2006; 60: 472-8.
128. Hindmarch I, Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum Psychopharmacol 2010; 25: 193-200.
129. Furuse T, Hashimoto K. Fluvoxamine monotherapy for psychotic depression: the potential role of sigma-1 receptors. Ann Gen Psychiatry 2009; 8: 26.
130. Kishimoto A, Todani A, Miura J, Kitagaki T, Hashimoto K. The opposite effects of fluvoxamine and sertraline in the treatment of psychotic major depression: a case report. Ann Gen Psychiatry 2010; 9: 23.
131. Shirayama Y, Hashimoto K. A Case of Psychotic Depression Treated with Fluvoxamine Monotherapy. Clin Psychopharmacol Neurosci 2010; 8: 53-4.
132. Bellini L, Gasperini M, Gatti F, Franchini L, Smeraldi E. In: Langer SZ, Ed. Critical issues in the treatment of affective disorders. Basel, Switzerland: Karger Press. 1994; pp. 32-6.
133. Gatti F, Bellini L, Gasperini M, Perez J, Zanardi R, Smeraldi E. Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry 1996; 153: 414-6.
134. Zanardi R, Franchini L, Gasperini M, Smeraldi E, Perez J. Longterm treatment of psychotic (delusional) depression with fluvoxamine: an open pilot study. Int Clin Psychopharmacol 1997; 12: 195-7.
135. Zanardi R, Franchini L, Gasperini M, Lucca A, Smeraldi E, Perez J. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study. J Clin Psychopharmacol 1998; 18: 441-6.
136. Zanardi R, Franchini L, Serretti A, Perez J, Smeraldi E. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. J Clin Psychiatry 2000; 61: 26-9.
137. Zanardi R, Franchini L, Gasperini M, Perez J, Smeraldi E. Doubleblind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry 1996; 153: 1631-3.
138. Hayashi T, Su T. Understanding the role of sigma-1 receptors in psychotic depression. Psychiatric Times 2005; 22: 54-63.
139. Stahl SM. Antidepressant treatment of psychotic major depression: potential role of the sigma receptor. CNS Spectr 2005; 10: 319-23.
140. Fong TG, Tulebaev SR, Inouye SK. Delirium in elderly adults: diagnosis, prevention and treatment. Nat Rev Neurol 2009; 5: 210-20.
141. Furuse T, Hashimoto K. Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer's disease. Ann Gen Psychiatry 2010; 9: 6.
142. Furuse T, Hashimoto K. Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases. Ann Gen Psychiatry 2010; 9: 18.
143. Furuse T, Hashimoto K. Sigma-1 receptor agonist fluvoxamine for postoperative delirium in older adults: report of three cases. Ann Gen Psychiatry 2010; 9: 28.
144. Hashimoto K, Furuse T. Sigma-1 receptor agonist fluvoxamine for delirium in elderly adults. Int J Geriatr Psychiatry 2011; in press.